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RESEARCH
First-in-human study of TK-positive oncolytic 
vaccinia virus delivered by adipose stromal 
vascular fraction cells
Boris R. Minev1,2*† , Elliot Lander3†, John F. Feller4, Mark Berman3, Bernadette M. Greenwood4, Ivelina Minev1, 
Antonio F. Santidrian1, Duong Nguyen1, Dobrin Draganov1, Mehmet O. Killinc1, Anna Vyalkova5, 
Santosh Kesari6, Edward McClay7, Gabriel Carabulea8, Francesco M. Marincola9, Lisa H. Butterfield10 
and Aladar A. Szalay1,2,5
Abstract 
Background: ACAM2000, a thymidine kinase (TK)-positive strain of vaccinia virus, is the current smallpox vaccine in the 
US. Preclinical testing demonstrated potent oncolytic activity of ACAM2000 against several tumor types. This Phase I clini-
cal trial of ACAM2000 delivered by autologous adipose stromal vascular fraction (SVF) cells was conducted to determine 
the safety and feasibility of such a treatment in patients with advanced solid tumors or acute myeloid leukemia (AML).
Methods: Twenty-four patients with solid tumors and two patients with AML participated in this open-label, non-
randomized dose-escalation trial. All patients were treated with SVF derived from autologous fat and incubated for 
15 min to 1 h with ACAM2000 before application. Six patients received systemic intravenous application only, one 
patient received intra-tumoral application only, 15 patients received combination intravenous with intra-tumoral 
deployment, 3 patients received intravenous and intra-peritoneal injection and 1 patient received intravenous, intra-
tumoral and intra-peritoneal injections. Safety at each dose level of ACAM2000 (1.4 × 106 plaque-forming units (PFU) 
to 1.8 × 107 PFU) was evaluated. Blood samples for PK assessments, flow cytometry and cytokine analysis were col-
lected at baseline and 1 min, 1 h, 1 day, 1 week, 1 month, 3 months and 6 months following treatment.
Results: No serious toxicities (> grade 2) were reported. Seven patients reported an adverse event (AE) in this study: 
self-limiting skin rashes, lasting 7 to 18 days—an expected adverse reaction to ACAM2000. No AEs leading to study 
discontinuation were reported. Viral DNA was detected in all patients’ blood samples immediately following treat-
ment. Interestingly, in 8 patients viral DNA disappeared 1 day and re-appeared 1 week post treatment, suggesting 
active viral replication at tumor sites, and correlating with longer survival of these patients. No major increase in 
cytokine levels or correlation between cytokine levels and skin rashes was noted. We were able to assess some initial 
efficacy signals, especially when the ACAM2000/SVF treatment was combined with checkpoint inhibition.
Conclusions: Treatment with ACAM2000/SVF in patients with advanced solid tumors or AML is safe and well toler-
ated, and several patients had signals of an anticancer effect. These promising initial clinical results merit further 
investigation of therapeutic utility.
Trial registration Retrospectively registered (ISRCTN#10201650) on October 22, 2018.
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Background
Due to the vast knowledge expansion in tumor immunol-
ogy in recent years, immunotherapy is quickly becoming 
a major cancer treatment modality [1]. At the same time, 
several major obstacles to the successful cancer immuno-
therapy are emerging. Immune suppressive microenvi-
ronment at tumor sites is a significant hindrance, leading 
to limited responsiveness to modern immunotherapeu-
tic agents in many tumor types [2]. These “cold” tumors 
are lacking infiltration of Th1-polarized immune effector 
cells and this characteristic is generally associated with 
poor clinical prognosis [3, 4, 5] and diminished likelihood 
of responding to immunotherapy such as checkpoint 
inhibitor therapy [6].
A promising strategy to activate the immune system 
at the tumor sites is the use of oncolytic viruses. Many 
recent studies are confirming the ability of oncolytic 
viruses to enhance immune cell infiltration, thus convert-
ing “cold” tumors into “hot” tumors, potentially leading 
to a better responsiveness to the current combination 
immunotherapy approaches [7–9].
Currently, a number of oncolytic viruses including vac-
cinia virus, herpes simplex virus-1, adenovirus, ECHO-
7, seneca valley virus, reovirus and other viruses are at 
various stages of clinical development [10]. The ideal 
oncolytic virus would be very safe to treat even severely 
immuno-suppressed cancer patients, would have potent 
anti-tumor properties against multiple tumor types, and 
would be able to attack and kill all tumor cells at distant 
metastatic sites. It would be easily manufactured and 
stored for widespread use. Further, the need for genetic 
manipulation of the virus would be minimal. None of the 
viruses currently under investigation has the ability to 
fulfill this ideal viral phenotype. However, the oncolytic 
vaccinia virus may satisfy many of the above criteria.
Vaccinia virus (VV) is a large and complex particle con-
taining a single linear double-stranded DNA genome of 
approximately 190  kb, encoding approximately 150–200 
proteins [11]. This virus has many characteristics desir-
able in an oncolytic virus for clinical applications: (1) 
short, well-characterized life cycle, spreading very rapidly 
from cell-to-cell, (2) highly cytolytic for a broad range of 
tumor cell types, (3) a large insertion capacity (> 25  kb) 
for the expression of exogenous genes if required, (4) 
high genetic stability, (5) amenable to large scale produc-
tion of high levels of infectious virus; (6) does not cause 
any known diseases in humans, (7) remains in the cyto-
plasm and does not enter the host cell nucleus during the 
entire life cycle, and thus does not integrate into the host 
genome, (8) used extensively as smallpox vaccine in mil-
lions of people with well documented safety profile [12], 
(9) drugs (e.g. vaccinia immunoglobulin, cidofovir, etc.) 
are available to effectively treat any potential vaccinia 
infections, and (10) has previously been safely adminis-
tered to patients with advanced cancer [13] [14].
Majority of known VV strains were used as vaccines 
in the World Health Organization Smallpox Eradication 
Program (1966–1980). In the US, the main VV strain 
used was Dryvax—used as smallpox vaccine until 2008 
when it was substituted by ACAM2000 (Acambis, Inc.™), 
a single plaque-purified vaccinia virus derivative of Dry-
vax [15, 12], selected based on its reduced virulence [16, 
17].
ACAM2000 genome carries key genomic altera-
tions that explain its reduced virulence [18]. Two main 
disrupted factors are immunomodulatory: (i) a tumor 
necrosis factor receptor, and (ii) the interferon α/β bind-
ing protein [18]. Moreover, ACAM2000 genome presents 
other genomic alterations that might contribute to its 
naturally occurring reduced virulence, namely a trunca-
tion of ankyrin-repeat ortholog of a VARV (Variola)-and 
CPXV (cowpox)-like protein and a short form of the thy-
midylate kinase gene [18].
To reduce the risk of therapeutic use of vaccinia virus, 
highly virulent vaccinia virus strains like Western Reserve 
have been genetically-engineered to attenuate the virus 
and to improve safety [19–21]. Elimination of TK gene 
from the virulent Western Reserve strain decreased sig-
nificantly the lethality of mice injected intra-cranially 
with the virus [21]. Therefore, the TK gene from vaccinia 
virus genome became the primary target to attenuate 
highly virulent viruses or viruses with unknown viru-
lence. In contrast, the ACAM2000 derivation exempli-
fies an alternative strategy to generate a safer vaccinia 
virus: selection of a naturally occurring clone with a sig-
nificantly reduced virulence and improved safety profile. 
Therefore, the TK-positive ACAM2000 possesses both 
strong anti-tumor activities associated with unattenuated 
viruses and a significant safety profile due to the natural 
clonal selection.
Although the safety profile of ACAM2000 is well estab-
lished, a possible concern for the use of this virus in 
cancer patients is increased toxicity due to virus amplifi-
cation within the tumor and cancer-related immunosup-
pression as commonly observed particularly in advanced 
stage patients [22].
In preclinical studies we confirmed that ACAM2000 
is a very potent oncolytic virus, able to infect and kill 
multiple human cancer cells lines in  vitro (Table  1). 
However, we and others confirmed that the comple-
ment system can neutralize most of the viral parti-
cles after intravenous deployment [23]. Therefore, we 
suggested that the viral particles taken up by autolo-
gous SVF cells would be protected from the patients’ 
immune system, thus allowing effective delivery to 
the tumor sites. In addition, SVF contains stem cells 
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exhibiting a natural tropism towards tumor sites, which 
could be exploited to transport the viral payloads 
directly to the tumor sites [24]. Therefore, we designed 
a clinical trial utilizing autologous SVF cells incubated 
with vaccinia virus (ACAM2000/SVF) in patients with 
advanced solid tumors or AML. The current study is a 
first-in-human trial to determine the safety and feasi-
bility of this approach in patients with advanced solid 
cancers or AML.
Methods
Therapeutic efficacy of ACAM2000 in vitro
We analyzed the anticancer therapeutic efficacy of 
ACAM2000 in vitro against human prostate cancer cell 
lines PC3 and DU145, triple negative breast cancer cells 
MDA-MB-231 and lung adenocarcinoma line A549. 
Tumor cells were seeded on 96-well plates 24 h prior to 
infection. The following day, cells were almost conflu-
ent and were infected with 50 μl of DMEM media sup-
plemented with 2% fetal bovine serum (FBS) containing 
appropriate amount of ACAM2000 (MOI of 1). Control 
cells were left untreated. After 1  h of incubation the 
media were replaced with DMEM supplemented with 
10% FBS. Tumor cell death was then analyzed 24, 48, 
72 and 96 h post treatment by MTT assay as follows. At 
24, 48, 72, or 96 h after infection of cells, medium was 
replaced by 100 uL MTT solution at a concentration 
of 2.5 mg/ml MTT dissolved in DMEM and incubated 
for 2 h at 37 °C in a 5%  CO2 atmosphere. After removal 
of the MTT solution, the color reaction was stopped 
by adding 150 uL 1 N HCl diluted in isopropanol. The 
optical density was then measured at a wavelength of 
570 nm with a reference wavelength of 650. Uninfected 
cells were used as reference and were considered as 
100% viable.
Clinical trial
This open-label, non-randomized dose-escalation trial 
was approved by the International Cell Surgical Society 
Institutional Review Board. Written informed consent 
was obtained from all patients prior to treatment, and the 
study was conducted in compliance with Good Clinical 
Practice guidelines.
Eligibility
Patients (≥ 18  years) were required to have a histologi-
cally proven, primary or recurrent, advanced (staging 
defined by the American Joint Committee on Cancer 
(AJCC; 7th Edition) stage III or IV, and/or aggressive 
(defined as published disease-specific survival rates less 
than 20% at 5  years following best currently available 
therapies) solid organ cancers. Two IRB exemptions were 
made to include two patients with AML. All patients had 
to be able to understand and be willing to sign a writ-
ten informed consent. They had to have no continuing 
acute toxic effects of any prior therapy, including but 
not limited to biological therapy, radiotherapy, chemo-
therapy, or surgical procedures, i.e., all such effects 
must have resolved to Common Terminology Criteria 
for Adverse Events (CTCAE, Version 4.0) Grade ≤ 1. Any 
other surgery (except biopsies) must have occurred at 
least 28  days prior to study enrollment. ECOG perfor-
mance Status of 0 to 2 was acceptable. A life expectancy 
of at least 3 months was required. Also, adequate organ 
and marrow function was required, as follows: Absolute 
neutrophil count (ANC) ≥ 1.5 ×  109; Platelets ≥ 100 × 
 109 (without platelet transfusion); Hemoglobin ≥ 9.0  g/
dL (with or without red blood cell (RBC) transfusion); 
Serum creatinine ≤ 1.5 × upper limit of normal (ULN); 
Bilirubin ≤ 1.5 × ULN; ALT and AST at ≤ 2.5 × ULN 
(in case of liver metastasis AST/ALT at ≤ 5.0 × ULN); 
LDH ≤ 1.5 × ULN. Women of child-bearing potential 
and men with partners of child-bearing potential had to 
agree to use adequate contraception (hormonal or barrier 
method of birth control; abstinence) prior to study entry, 
for the duration of study participation, and for 90  days 
following completion of therapy. Women of child-bearing 
potential had to have negative pregnancy test prior to ini-
tiating study drug dosing. All patients had to be willing 
and able to comply with scheduled visits, the treatment 
plan, imaging and laboratory tests.
Excluded from the study were all patients with a cur-
rent or anticipated use of other investigational agents or 
marketed anticancer agents. Also excluded were patients 
who have received chemotherapy or radiotherapy within 
4 weeks prior to entering the study or has not recovered 
from adverse events due to agents administered more 
than 4  weeks earlier. Other exclusion criteria included 
immune system disorders (including acquired immuno-
deficiency syndrome (AIDS), HIV infection or hepatitis 
B or C); Patients who were receiving additional immu-
nosuppressive therapy or any steroids (except concur-
rent corticosteroid usage if no more than 20 mg per day, 




Human tumor cell line (percent viability)
PC3 DU145 MDA-MB-231 A549
24 67 100 85 80
48 64 80 63 45
72 33 66 36 41
96 13 51 21 30
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prednisolone equivalent is applied); Patients who have 
received prior gene therapy or therapy with cytolytic 
virus of any type; Patients with clinically significant car-
diac disease (New York Heart Association Class III or IV) 
including pre-existing arrhythmia, uncontrolled angina 
pectoris, and myocardial infarction 1 year prior to study 
entry, or Grade 2 or higher compromised left ventricular 
ejection fraction; Patients with dementia or altered men-
tal status that would prohibit informed consent; patients 
with severe or uncontrolled medical disorder that would, 
in the investigator’s opinion, impair ability to receive 
study treatment (i.e., uncontrolled diabetes, chronic renal 
disease, chronic pulmonary disease or active, fever, sys-
temic and/or uncontrolled infections, psychiatric illness/
social situations that would limit compliance with study 
requirements); patients receiving concurrent antiviral 
agent active against vaccinia virus (e.g., cidofovir, vaccinia 
immunoglobulin, imatinib, ST-246) during the course of 
study; patients with known allergy to ovalbumin or other 
egg products; patients with clinically significant dermato-
logical disorders (e.g., eczema, psoriasis, or any unhealed 
skin wounds or ulcers) as assessed by the Principal Inves-
tigator during screening and during the study; patients 
with a history of allergy to iodinated contrast media; 
patients with an active dental infection or recent dental 
work within 2 weeks of deployment; patients with known 
brain metastases were excluded from this clinical trial 
because of their poor prognosis and because they often 
develop progressive neurologic dysfunction that would 
confound the evaluation of neurologic and other adverse 
events.
Treatment
Patients were admitted to the outpatient clinic and a 
mini-liposuction procedure was performed to isolate up 
to 100 milliliters of adipose tissue. All patients received 
local anesthesia consisting of lidocaine 0.5% with epi-
nephrine 1:400,000 with  HCO3 8.4% titrated to pH of 7.4. 
Then sterile prep was performed, followed by liposuction 
procedure utilizing the Time-Machine™ device, fat pro-
cessing unit (syringe) and 2.5–3  mm cannula. Bacitra-
cin ointment and a small bandage were secured over the 
wound along with a compressive bandage. The SVF cells 
were prepared in a closed system according to an estab-
lished protocol [25]. Specific amounts of isolated adipose 
tissue, numbers of isolated SVF cells and their viability 
levels are listed in Table 2.
The ACAM2000 vaccine was prepared according to 
manufacturer’s protocol. After reconstitution of the lyo-
philized preparation, each vial contained approximately 
2.5–12.5 × 107 plaque-forming units (pfu) of live vaccinia 
virus. Specific amount of ACAM2000 vaccine was added 
to a labeled 20  cc syringe containing the SVF cells to 
achieve multiplicity of infection (MOI) = 1. The syringe 
was then placed on a rotator inside a 37° incubator, and 
was incubated for 15 min to 1 h with constant rotation at 
20 rpm.
Twenty-four patients with solid tumors and two 
patients with AML received a single treatment with 
ACAM2000/SVF. Six patients received systemic intra-
venous application only, one patient received intratu-
moral application only, 15 patients received combination 
intravenous with intra-tumoral deployment, 3 patients 
received intravenous and intra-peritoneal injection and 
1 patient received intravenous, intra-tumoral and intra-
peritoneal injections. To confirm the safety and toler-
ability of ACAM2000/SVF treatment, a dose escalation 
was incorporated into the study design. The dose range 
for ACAM2000 in this trial was between 1.4 × 106 and 
1.8 × 107 pfu.
Table 2 Isolation of  adipose tissue and  characterization 
of SVF cells
Patients’ adipose tissue was obtained aseptically in the operating room and 









1 40 34 × 106 76
3 50 34 × 106 87
4 50 196 × 106 62
5 50 67 × 106 95
8 30 29 × 106 94
10 50 214 × 106 86
14 50 19 × 106 78
15 100 42 × 106 86
18 40 30 × 106 96
21 50 216 × 106 92
22 51 46 × 106 91
23 50 80 × 106 93
24 51 147 × 106 88
25 50 20 × 106 65
26 50 59 × 106 70
27 29 14 × 106 82
28 90 9.4 × 106 46
29 50 49 × 106 84
30 90 32 × 106 78
31 10 54 × 106 75
32 50 20 × 106 75
33 50 32 × 106 77
34 50 66 × 106 60
35 50 114 × 106 86
36 50 94 × 106 79
47 50 46 × 106 47
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Deployment methods
Specific doses of injected SVF cells loaded with 
ACAM2000 at each route of administration are listed in 
Table 3.
a. Intravenous: the non-expanded, autologous stromal 
vascular fraction (SVF) extracted from up to 100 ml 
of lipoaspirate and purified by collagenase digestion 
and a series of washing steps and containing up to 
100 million cells incubated with vaccinia virus was 
delivered by intravenous injection in a volume of 
20 mL.
b. Intra-tumoral: the SVF incubated with vaccinia virus 
was delivered by intra-tumoral injection at the inves-
tigator’s clinical site or at Desert Medical Imaging 
with CT guidance or MRI guidance. The injection 
volume and number of injected cells varied depend-
ing on tumor type and tumor size and location.
c. Intra-peritoneal: the SVF incubated with vaccinia 
virus was delivered by intra-peritoneal injection at 
the investigator’s clinical site or at Desert Medical 
Imaging with ultrasound guidance. The injection vol-
ume and number of injected cells varied depending 
on tumor type.
Safety assessments
A complete medical history was taken and a physical 
examination performed at screening.
Adverse events were monitored throughout the study 
until resolution. In addition, all patients responded to a 
weekly questionnaire answering specific questions on 
their current condition.
Pharmacokinetics of ACAM2000
We analyzed the pharmacokinetics of ACAM2000 by 
quantifying the amount of viral DNA present in the 
peripheral blood of patients treated with ACAM2000/
SVF by quantitative PCR (qPCR). Specifically, 0.5–5  ml 
peripheral blood from the treated patients were col-
lected in Vacutainer K2EDTA blood collection tubes 
(Becton, Dickinson, NJ) before treatment, 1 min, 60 min, 
1  day, 1  week, 1  month, 3  month and 6  months after 
treatment. DNA was extracted using the Quick-gDNA™ 
Blood MidiPrep (Zymo Research, CA). The copy num-
ber amount of the ACAM2000 gene A56R was quanti-
fied by qPCR using PowerUp™SYBR® Green Master Mix 
(Thermofisher, CA) and the following primers: A56R-F 
CAT (CAT CTG GAA TTG TCA CTA CTA AA), A56R-
R (ACG GCC GAC AAT ATA ATT AAT GC) described 
previously by Dr. Damon group at Poxvirus and Rabies 
Branch, Division of Viral and Rickettsial Diseases 
National Center for Zoonotic, Vector-Borne and Enteric 
Diseases, Centers for Disease Control and Prevention 
(CCID/CDC) [26]. A pUC57 plasmid containing a sin-
gle copy of A56R open reading frame from ACAM2000 
was created (Vectorbuilder—Cyagen Biosciences Inc, 
CA, USA) for use as a positive control and to generate a 
standard curve for the qPCR assays. Data were recorded 
and analyzed using an ABI-PRISM 7700 Sequence Detec-
tion System (Applied Biosystems) and Sequence Detector 
Software (SDS v2.2).
Flow cytometry and cytokine analysis
Blood samples for PBMC Flow Cytometry and Cytokine 
analysis were collected in Vacutainer Heparin blood 
collection tubes at Baseline and 1 day, 1 week, 1 month, 
3 months and 6 months following the treatment. PBMC 
were isolated by Ficoll-Paque method. Plasma samples 
for cytokines analysis were isolated by centrifugation of 
Table 3 Routes of administration and dose of injected SVF 
cells loaded with ACAM2000
Patients’ SVF cells were isolated and incubated with ACAM2000 at a ratio of 1:1 
(MOI 1) before the I.V., I.T. and I.P. injections
Patient
ID
Route of administration and dose (SVF cell numbers)
I.V. I.T. I.P. Total
1 2.5 × 106 2.5 × 106
3 1.4 × 106 1.6 × 106 3 × 106
4 3 × 106 3 × 106
5 3 × 106 3 × 106 6 × 106
8 4.6 × 106 2.4 × 106 7 × 106
10 1.2 × 107 6 × 106 1.8 × 107
14 1.5 × 106 1.5 × 106 3 × 106
15 3.1 × 106 4.8 × 105 3.6 × 106
18 3 × 106 3 × 106
21 2 × 106 1 × 106 3 × 106
22 1 × 106 2 × 106 3 × 106
23 3 × 106 3.6 × 106 6.6 × 106
24 6.6 × 106 6.6 × 106 1.3 × 107
25 1 × 106 2 × 106 3 × 106
26 2.1 × 106 9 × 105 3 × 106
27 2.1 × 106 9 × 105 3 × 106
28 2.1 × 106 9 × 105 3 × 106
29 3 × 106 3 × 106
30 8.4 × 105 5.6 × 105 1.4 × 106
31 7.5 × 105 6.5 × 105 1.4 × 106
32 7 × 105 7 × 105 1.4 × 106
33 6.5 × 105 5.4 × 105 2.2 × 105 1.4 × 106
34 3 × 106 3 × 106
35 7 × 105 7 × 105 1.4 × 106
36 1.4 × 106 1.4 × 106
47 5 × 106 5 × 106
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blood sample. All PBMC and Plasma samples were sent 
for analysis to the Immunologic Monitoring Laboratory 
(IML) at the University of Pittsburgh Cancer Institute. 
The IML has an independently monitored and exten-
sive quality control (QC) and quality assurance (QA) 
program to ensure the validity of test results and safety/
quality of therapeutic products, and participates in 
external proficiency panels. The IML also serves as the 
Central Immunology Laboratory for the Eastern Coop-
erative Oncology Group (ECOG). All activities were 
carried out in accordance with Good Laboratory Prac-
tices as outlined in Title 21 of the U.S. Code of Federal 
Regulations Part 58, using Standard Operating Proce-
dures (SOP) and including appropriate quality control.
Efficacy evaluation
Although this Phase I clinical study was designed to 
establish the safety and tolerability of ACAM2000/
SVF, we were able to assess some initial efficacy sig-
nals following treatment with the ACAM2000/SVF 
combination. Brief case reports for two of the respond-
ing patients are presented in the results section. Most 
patients were not evaluable by response evaluation cri-
teria for solid tumors (RECIST) criteria, because all of 
their tumors were not measured over time.
Statistical methods
Descriptive statistics for the safety and efficacy assess-
ments were calculated and displayed by group. Kaplan-
Meyer curves displaying the percentage of patients who 
survived after a given number of months were calcu-
lated for various groups in order to detect whether the 
treatment with ACAM2000/SVF had an effect on sur-
vival. Patients who dropped out of the study before it 
was completed were censored from the calculation of 
the survival curves. The set of curves were for patients 
with: (a) present skin rashes; (b) persistent viral DNA 
in the blood, and (c) for patients who had both persis-
tent viral DNA in the blood and skin rashes (Fig. 3). For 
each group of patients, both a Gehan-Breslow-Wlcoxon 
and Mantel-Cox t-tests were used to determine any 
degree of statistical significance, and the median sur-
vival rates were calculated for all groups.
Results
ACAM2000 is effective against multiple human tumor cell 
lines in vitro
ACAM2000 virus strain killed all tested human can-
cer cell lines efficiently, including prostate cancer cell 
lines PC-3 and DU154, triple negative breast cancer 
cells MDA-MB-231 and lung adenocarcinoma line A549 
(Table 1).
Patient demographics
As shown in Table  4, twenty-six patients were enrolled 
in this study—15 male and 11 female patients. Twenty-
four patients with 15 different solid tumor types and 2 
patients with AML were enrolled.
Toxicity
As shown in Table  5, self-limiting skin rashes and 
small lipo-puncture bleeding were the only treatment-
related adverse events in this study. These self-limiting 
skin rashes are an expected adverse reaction to the 
ACAM2000 administration. No other treatment-related 
AEs were reported. No infusion-related AEs were 
reported. No AEs leading to study discontinuation were 






 Male 15 58
 Female 11 42
Cancer type N %
 Lung cancer 1 4
 Breast cancer 2 8
 Prostate cancer 3 12
 AML 2 8
 Pancreatic cancer 2 8
 Colorectal cancer 2 8
 Head and Neck cancer 4 15
 Adrenal cancer 1 4
 Liver cancer 1 4
 Astrocytoma 1 4
 Bronchial carcinoid 1 4
 Ovarian cancer 1 4
 Uterine cancer 1 4
 Sarcomatoid 1 4
 Squamous cell carcinoma neck 1 4
 Esophageal cancer 1 4
 Thyroid cancer 1 4
Route of administration N %
 Intravenous (IV) 6 23
 Intravenous + Intratumoral 15 58
 Intratumoral (IT) 1 4
 Intraperitoneal (IP) +IV 3 12
 IV + IT + IP 1 4
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in the type or severity of AEs that occurred following 
ACAM2000/SVF treatment. Three patients had presence 
of viral DNA in peripheral blood 1 month after treatment 
without experiencing any AE.
Another important finding of this study was that 18 
patients experienced virus-related and inflammation-
related symptoms at the tumor sites approximately 
2  weeks after treatment. Specifically, patients described 
this effect as “burning sensation”, fullness, heaviness and 
warmness, pointing at their respective tumor/metastatic 
sites—a condition lasting 2–4  weeks. These symptoms 
were self-limiting and did not require any treatment.
Flow cytometry and cytokine analysis
Flow cytometry results: Flow cytometry data on patient-
derived PBMCs indicated that treatment resulted in 
delayed changes that occurred gradually and over 
extended periods of time post treatment and without any 
dramatic immediate effects that can be linked to poten-
tial serious side effects or toxicities (Table 6).
Cytokine analysis results: Analysis of the concentra-
tions of 30 cytokines in the plasma of treated patients 
did not reveal any significant and consistent increase 
in cytokine levels post treatment. Particular attention 
was given to IL-6 levels, as this cytokine has already 
been linked to life threatening toxicities during cytokine 
release syndrome (CRS). Higher baseline IL-6 levels were 
observed in some patients but these remained under 
1000  pg/ml far below the 10,000  pg/ml seen in CRS 
patients, and were not further increased following ther-
apy. Il-6 levels did increase over time in some patients 
with lower baseline levels of IL-6 but these changes 
occurred gradually and similar to the observed gradual 
increase in VEGF or HGF levels likely reflecting corre-
sponding increases in tumor burden/progression. Inter-
estingly strong trends towards increased plasma levels 
of cytokines and chemokines associated with protective 
anti-tumor immunity was also evident including: IL-1b, 
IL-12, MIP1a, MIP1b, MCP-1, IL-15, IFNγ, IFNα, IL-1R, 
IP-10, MIG, IL-8.
All these responses, however, were delayed and took 
approximately 3  months to develop, and therefore can-
not be associated with any immediate cytokine release 
syndrome features or toxic side effects. Representa-
tive analysis of 9 cytokines and the relationship with the 
appearance of skin rashes in patients is presented on 
Fig. 1.
Pharmacokinetics of ACAM2000
In 10 out of 24 patients, ACAM2000 DNA was present 
in peripheral blood 1  week post treatment (Fig.  2). In 
8 out of those 10 patients, viral DNA was not detected 
on day 1 post treatment. In 1 of those 10 patients, viral 
DNA was lower on day 1 than on day 7 post treatment. 
These results indicate that viral DNA present 1  week 
after treatment might be originating from ACAM2000 
active replication, probably at tumor sites. In 3 out of 
21 patients, ACAM2000 DNA was present in peripheral 
blood 1 month post treatment. In one of those 3 patients, 
ACAM2000 DNA was present 3 months post treatment. 
No ACAM2000 DNA was detected 6 months post treat-
ment in any patient.
Efficacy assessment
An important observation in this study was that 
patients with evidence for oncolytic virus activity, 
including persistance of viral DNA in the blood from 
1 week to 3 months following treatment, or having skin 
rashes, demonstrated trends towards longer survival 
(Fig.  3). The patients who presented with both persis-
tent viral DNA in the blood and skin rashes showed 
strongest trend towards longer survival (Fig.  3c). For 
the 11 patients with persistent viral DNA in the blood, 
the median survival was 10 months, compared to only 
5  months for the patients without persistent viral 
DNA in the blood. However, despite these results, the 
Table 5 Adverse events
a/t: After treatment; pt: patient
Adverse events Number % Related Resolved
Skin rashes 8 40 Yes Yes
Lipo- puncture bleeding 1 5 Yes Yes
Fever (100.5 F) 2 10 No (10 days and 16 days a/t) Yes
Pain 4 20 No (7 days, 10 days and 1 month a/t) Yes
Hemoptysis 1 5 No (2 months a/t) Yes
Pleural effusion 1 5 No (3 months a/t) Yes
Headache and weakness of one side 1 5 No (3 weeks a/t) Yes
Blood Transfusion 1 5 No (10 days a/t) Yes
Pneumonia 1 5 No (16 days a/t) Yes
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survival curves were not statistically significantly dif-
ferent from one another. This is due to the limited 
number of patients and/or differences in disease type/
progression that preclude proper and conclusive evalu-
ation of therapeutic benefits at this stage. A median 
survival period of 5 months was also calculated for the 
sub-cohort of 17 patients in whom no skin rashes were 
detected (Fig.  3a), although it should be emphasized 
again that no statistically significant differences were 
noted amongst the survival curves.
The main purpose of this Phase I clinical study was 
to establish the safety and tolerability of ACAM2000/
SVF, as this approach is being tested for the first time in 
patients with advanced solid tumors and AML. However, 
we were able to assess some initial efficacy signals in sev-
eral patients.
Patient #21 was 70  years old male diagnosed with 
metastatic poorly differentiated squamous cell carci-
noma (Stage: IVB). Patient presented with a very large 
tumor near right ear heading toward collar bone and 
other smaller tumors on the opposite side. Patient pre-
viously received XRT to right lesion as well as Paclitaxel 
and 5FU. Treatment with ACAM2000/SVF was divided 
in 4 independent inoculations performed the same day: 
an IV infusion of ACAM2000/SVF and 3 IT injections 
into three regions of his right neck tumor. Three weeks 
Table 6 Representative analysis of main cell populations in patients
Patients’ blood samples were analyzed by flow cytometry at different time-points after treatment: B: baseline; 1 w: 1 week post treatment; 1 m: 1 month post 
treatment. Data represent percent of total PBMC. Cell populations:  TCD4 (CD3+ CD4 +),  TCD8 (CD3+ CD8 +), NK (CD3−CD56 +), MDSC (Lin-DR-CD3 + CD116+), Tem 
(CD3+ CD8+ CD45RA-CD197−), Tcm (CD3+ CD8+ CD45RA−CD197+)
Patient ID TCD4 TCD8 NK
B 1 w 1 m B 1 w 1 m B 1 w 1 m
3 24.8 20.0 27.4 20.1 20.1 27.2 8.9 – 10.4
5 8.0 3.4 5.6 3.9 2.6 2.6 19.9 13.5 23.4
8 – 12.9 14.1 – 8.5 10.2 – 3.1 6.6
10 13.4 13.6 9.6 8.5 18.7 17.5 7.3 – –
14 30.8 35.7 36.9 32.3 31.0 28.6 5.0 3.7 3.1
15 12.6 9.2 79.9 7.8 8.0 7.3 16.3 12.6 13.9
18 12.9 11.6 13.6 4.1 8.8 5.7 11.1 3.6 10.3
21 13.8 17.9 14.6 3.4 4.1 4.0 17.6 15.9 21.7
24 49.0 32.3 51.0 6.0 3.7 6.1 6.9 3.3 5.7
26 15.0 16.6 14.1 15.9 16.3 13.7 20.9 21.0 16.1
27 22.4 19.1 8.9 9.3 11.5 3.8 4.8 10.3 6.4
28 48.2 36.4 41.9 5.2 6.5 5.6 – 8.6 6.5
29 0.4 0.6 0.6 1.2 2.1 1.7 1.6 2.2 1.7
30 22.6 22.9 23.7 8.6 7.1 14.3 6.3 6.0 6.4
Patient ID MDSC Tem Tcm
B 1 w 1 m B 1 w 1 m B 1 w 1 m
3 0.6 0.6 – 1.8 2.1 2.9 1.5 1.6 2.3
5 1.8 2.3 2.3 0.5 0.3 0.5 0.5 0.3 0.3
8 – 2.7 2.1 – 3.6 3.7 – 0.3 0.3
10 1.6 – 2.0 0.5 – 2.3 0.2 – 0.4
14 0.5 0.8 0.3 3.8 3.5 3.1 19.8 17.1 14.8
15 1.1 2.0 1.2 2.1 2.7 2.3 0.5 0.6 0.8
18 2.0 1.9 3.5 0.9 3.2 1.8 0.0 0.1 0.0
21 1.7 2.4 1.7 1.2 1.3 1.4 0.0 0.1 0.1
24 0.3 0.9 0.9 0.5 0.4 0.4 1.2 0.7 1.1
26 0.5 0.7 1.1 2.3 2.6 2.2 0.1 0.2 0.2
27 1.2 0.6 0.4 3.4 3.3 1.2 0.1 0.1 0.1
28 0.5 0.7 0.4 3.3 4.2 4.3 0.2 0.2 0.2
29 9.0 5.1 6.0 0.1 0.2 0.2 0.1 0.2 0.1
30 0.3 0.2 0.2 3.0 2.0 4.3 0.5 0.5 0.5
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post treatment the patient reported itchiness, warmth 
and slight enlargement of treated lesion as well as some 
oozing (Fig. 4). Biopsy of this lesion at 4 weeks post treat-
ment showed poorly differentiated squamous cell carci-
noma arranged in sheets and groups with comedo-type 
necrosis, inflammation and surrounding fibrovascular 
stroma. Six weeks post treatment patient began treat-
ment with Opdivo (Nivolumab, anti-PD-1) q2w 3  mg/
kg. Three months post ACAM2000/SVF treatment 
this patient received XRT (13 doses) accompanied with 
fatigue, nausea, and difficulty swallowing. Approximately 
2  weeks after completion of XRT treatment the tumor 
began shrinking, leading to a substantial size reduction at 
6  months post ACAM2000/SVF treatment, weight gain 
and significant improvement of overall condition (Fig. 4).
Patient #47 was 67 years old male diagnosed with met-
astatic papillary thyroid carcinoma with cervical lym-
phadenopathy. Left thyroidectomy and isthmectomy was 
done in 1985. Patient presented with a large clearly vis-
ible right supraclavicular lymph node, a smaller left cer-
vical node and several smaller palpable cervical nodes. 
Treatment with ACAM2000/SVF was divided in 6 inde-
pendent intra-tumoral inoculations performed the same 
day: 4 IT injections into four regions of the larger right 
supraclavicular lymph node and 2 IT injections into two 
regions of the smaller cervical lymph node. Ipilimumab 
(anti-CTLA-4) was injected 36  h post ACAM2000/SVF 
injections as a single IT injection of 25  mg Ipilimumab 
into the right node only. Approximately 4  weeks post 
treatment the patient reported enlarged, warmer and 
reddish right node and no inflammatory symptoms in 
the left node (Fig.  5). Two months post treatment the 
right tumor was much smaller, softer and much less 
inflamed, while no changes in consistence or appear-
ance were noted in the left treated node. Three months 
post treatment the patient experienced almost complete 
eradication of the right tumor with a very small hard area 
notable only on palpation (Fig. 5).
Discussion
This Phase I clinical study was designed to establish the 
safety and tolerability of ACAM2000/SVF and assess 
initial efficacy signals in relationship to ACAM2000/
SVF treatment. The most important finding of this study 
was that ACAM2000/SVF can safely be administered 
in patients with advanced metastatic solid tumors or 
advanced AML. Two important aspects of this finding 
will have clear clinical implications in future trials: (i) 
this is the first clinical study confirming the safety of a 
TK-positive oncolytic vaccinia virus delivered by autolo-
gous cells, and (ii) safety administration of ACAM2000/
SVF is confirmed in severely immunocompromised 
Fig. 1 Representative analysis of 9 cytokines and the relationship with the appearance of skin rashes in patients. Patients’ plasma samples were 
analyzed using The Cytokine Human Magnetic 30-Plex Panel for the Luminex™ platform (Thermo Fisher) at different time-points after treatment: 
1 W: 1 week post treatment; 1 M: 1 month post treatment. Data is presented as Log2 of fold change after treatment
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patients with advanced cancer. This trial also validates 
the safety of combining ACAM2000 and SVF as a deliv-
ery vehicle that protects the virus from complement 
inactivation in the blood. No significant treatment-asso-
ciated toxicities were observed in any of the 26 patients 
who received IV, IP and IT injections of ACAM2000 
loaded onto freshly isolated SVF, showing that ex  vivo 
infection of the SVF can be done in a manner that is safe 
to the patients.
Our pharmacokinetics data indicate that the injected 
virus (viral DNA detected by qPCR) is rapidly cleared 
from blood circulation within an hour. In some patients 
the viral DNA reappeared 1 week to 1 month following 
treatment, and importantly often in the absence of any 
Fig. 2 Viral DNA in patients’ peripheral blood. DNA was extracted using the Quick-gDNA™ Blood MidiPrep (Zymo Research, CA). The copy number 
amount of the ACAM2000 gene A56R was quantified by qPCR using PowerUp™  SYBR® Green Master Mix (Thermofisher, CA). Viral DNA was analyzed 
by qPCR before treatment (bt), and 1 min (1 min), 60 min (60 min), 1 day (1d), 1 week (1 w), 1 month (1 mo), 3 months (3 mo) and 6 months (6 mo) 
after treatment
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skin rashes which suggests intra-tumoral virus infection 
and amplification. Despite the potential for sustained 
intra-tumoral virus amplification, none of the treated 
patients developed uncontrolled viremia or manifested 
widely spread skin rashes or any other evidence for sys-
temic toxicity, supporting our conclusion that intra-
tumoral virus amplification does not pose a significant 
safety concern.
AEs associated with smallpox vaccination in general 
are fever, headache, myalgia, rigors, sweating, fatigue, 
asthenia, nausea, vomiting, general reddening of the 
skin, lymph node swelling, and immunological parame-
ter changes (e.g., cytokines). In the past, various vaccinia 
virus strains (DryVax, Lister) have been applied clini-
cally to cancer patients [13, 14, 27, 28]. Positive treatment 
results have been reported, along with some severe local 
reactions (rash, erythema) as well as systemic side effects 
(headache, malaise, fever, flu-like symptoms), but no life-
threatening toxicities. These previously published results 
provided the rationale and scientific justification for us 
to conduct further clinical investigation of the oncolytic 
potential of ACAM2000, the current plaque-purified and 
naturally attenuated smallpox vaccine. The most con-
cerning toxicities observed with the use of ACAM2000 
as a smallpox vaccine are rare cardiac complications 
(arrhythmias, pericarditis, myocarditis, and dilated car-
diomyopathy). No cardiac complications or systemic side 
effects were observed in any patient participating in the 
current trial. This finding contrasts with previous clinical 
trials with “naked” vaccinia viruses, where most patients 
experienced fever, chills and other flu-like symptoms for 
the first 6–24 h following treatment [13, 14].
We have demonstrated that ACAM2000 is oncolytic 
and efficiently infects and kills human cancer cell lines, 
while the extensive use of the same virus as a smallpox 
vaccine has conclusively demonstrated self-limiting 
amplification at the site of administration in the skin 
with virtually absent local or distant spread to other tis-
sues and organs in the body [15]. These observations 
likely reflect the combination of efficient neutralization 
in circulation and the inability of the virus to infect and 
amplify in healthy cells, apart from the limited amplifi-
cation seen in skin keratinocytes. This study confirmed 
the previous observations with various heterogeneous 
and more virulent smallpox vaccines previously licensed 
in the USA and Europe that the AEs associated with 
the application of smallpox vaccines to cancer patients 
are minor and rarely require medical attention [27, 28]. 
Overall, the observed treatment-related adverse events 
in the study were rare. These findings suggest that 
ACAM2000 is well tolerated and can be safely adminis-
tered to patients with cancer.
Despite this positive safety data, the investiga-
tor administering ACAM2000 must be prepared for 
extremely rare but possible severe local and systemic 
reactions, historically associated with patients who had 
inherent or treatment-related immunodeficiency. In 
the unlikely scenario that such complications do occur, 
the adverse events and complications can be effectively 
controlled by the available antidote vaccinia immune 
Fig. 3 Kaplan-Meier plots showing the relative survival of a total of 
25 patients (23 patients with solid tumors and 2 patients with AML). 
a Patient survival relative to the presence of persistent vaccinia virus 
DNA in the blood for 1 week to 3 months post treatment. Median 
survival: without persistent VV, 5 months, (n = 14) vs. with persistent 
VV, 10 months (n = 11). b Patient survival relative to reported 
presence of skin rashes. Median survival: without skin rashes, 
5 months (n = 17) vs. with skin rashes, undefined (n = 8). c Patient 
survival relative to the presence of both skin rashes and persistent 
vaccinia virus DNA in the blood. Median survival: with either or none, 
5 months, (n = 20) vs. with both, undefined (n = 5). Vertical tick marks 
indicate patients who dropped from the study or were censored from 
analysis after switching to alternative cancer treatments
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globulin (VIG) [29]. Although cardiac toxicities were 
not reported by any patient in our safety study, spe-
cific efforts should be taken to closely monitor the car-
diac condition of all patients undergoing ACAM2000 
treatment in an effort to detect such symptomatic or 
asymptomatic virus-related complications and prevent 
possible cardiac events by timely administration of the 
antidote, if considered necessary by the monitoring 
physician.
The therapeutic potential of any oncolytic virus 
depends on the fine balance between the induction of 
antiviral immunity, leading to clearance of the oncolytic 
virus, and the development of antitumor immunity, lead-
ing to tumor cell eradication and eventually to potent and 
durable clinical responses. The current trial represents an 
attempt to fine tune this balance by protecting the onco-
lytic virus using autologous SVF cells to avoid premature 
clearance of the virus, allowing sufficient time for viruses 
to replicate and kill tumor cells and to initiate antitumor 
immunity. Interestingly, the analysis of this safety trial 
suggests that there is no positive correlation between 
augmented vaccinia virus activity and increased tumor 
burden, tumor-associated immunosuppression, and 
shorter survival. Overall, the trends towards improved 
Fig. 4 Patient #21: tumor regression of patient’s poorly differentiated squamous cell carcinoma (Stage: IV_B)
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survival associated with vaccinia virus activity in  vivo 
including the persistence of viral DNA in the blood, vis-
ible skin rashes, and/or both (Fig. 3), are intriguing and 
may indeed have therapeutic significance.
The two case reports presented here emphasize the 
importance of combining checkpoint inhibitors and 
oncolytic viruses to achieve better clinical responses. 
The synergistic effects of this combination have been 
described previously by us [30] and other groups [31, 32]. 
Therefore, these current trial findings will be utilized in 
future clinical trial designs with this synergistic approach.
When evaluating the efficacy outcomes of the current 
study, it is important to note that the primary
objective of this study was to evaluate the safety of 
the combination of ACAM2000 and SVF in patients 
with advanced tumors. Therefore, we acknowledge 
that the interpretation of the efficacy outcomes is lim-
ited by the small size of the study population (n = 26). 
Only a randomized trial would be able to definitively 
demonstrate the efficacy of the ACAM2000/SVF 
combination.
Fig. 5 Patient #47: tumor regression of patient’s metastatic papillary thyroid carcinoma. Treatment effects in the treated right supraclavicular lymph 
node are shown
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Conclusions
The aggregate safety, tolerability, and PK results indicated 
that ACAM2000/SVF was well tolerated in this study 
with 26 patients with advanced cancers (Stage III or IV). 
The MTD was not reached.
In summary, our study show that: (i) the combined 
application of SVF and ACAM2000 was very safe in all 
patients; (ii) the results of the plasma cytokine assays 
suggested mild inflammatory reaction starting approxi-
mately 1  week after treatment, not associated with any 
clinical symptoms; (iii) most patients experienced virus-
related and inflammation-related symptoms at the tumor 
sites approximately 2 weeks after treatment; (iv) the flow 
cytometry assays show induction of immune response 
with memory T cells approximately 1 month after treat-
ment; (v) there is a trend towards improved survival asso-
ciated with vaccinia virus activity in  vivo including the 
persistence of viral DNA in the blood, visible skin rashes, 
and/or both; (vi) some patients experienced significant 
tumor size reduction, especially when the ACAM2000/
SVF treatment was combined with checkpoint inhibition.
These early promising results must be re-evaluated 
within a larger and more homogeneous cohort of patients 
to confirm the feasibility and effectiveness of this novel 
treatment approach.
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